Mayne Pharma Group Limited (ASX:MYX)
Australia · Delayed Price · Currency is AUD 3.250
+0.020 (0.62%)
Sep 2, 2026, 10:54 AM AEST
Mayne Pharma Group Financials Overview
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Revenue Revenue Growth | 383.68 | 383.68 | 408.1 | 388.4 | 183.59 | 157.15 |
Revenue Growth | -5.76% | -5.98% | 5.07% | 111.56% | 16.82% | -60.79% |
Gross Profit Gross Profit Growth | 248.07 | 248.07 | 247.27 | 218.78 | 83.49 | 71.57 |
Operating Income Operating Income Growth | -26.57 | -26.57 | -22.03 | -77.84 | -183.43 | -122.53 |
Net Income Net Income Growth | 24.47 | 24.47 | -93.84 | -174.23 | 117.25 | -281.29 |
Earnings Per Share EPS Growth | 0.21 | 0.21 | -1.19 | -2.19 | 1.43 | -3.42 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Dermatology Dermatology Growth | 138.7 | 138.7 | 154.09 | 174.86 | 56.99 | 92.21 |
Women's Health Women's Health Growth | 174.27 | 174.27 | 178.37 | 142.83 | 61.89 | 10.57 |
International International Growth | 70.71 | 70.71 | 75.64 | 70.71 | 64.7 | 54.37 |
Total Total Growth | 383.68 | 383.68 | 408.1 | 388.4 | 183.59 | 157.15 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Investments Cash & Investments Growth | 80 | 80 | 100.4 | 149.28 | 220.14 | 98.01 |
Total Debt Total Debt Growth | 43.2 | 43.2 | 41.27 | 38.82 | 47.51 | 413.67 |
Net Cash (Debt) Net Cash Growth | 36.81 | 36.81 | 59.13 | 110.46 | 172.64 | -315.66 |
Net Cash Growth | 47.33% | -37.76% | -46.47% | -36.02% | - | - |
Net Cash Per Share Net Cash Per Share Growth | 0.35 | 0.35 | 0.75 | 1.39 | 2.10 | -3.84 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 13.87 | 13.87 | 17.47 | -15.3 | -42.71 | -7.21 |
Capital Expenditures CapEx Growth | -2.95 | -2.95 | -12.28 | -7.95 | -8.34 | -10.01 |
Free Cash Flow Free Cash Flow Growth | 10.92 | 10.92 | 5.19 | -23.25 | -51.05 | -17.22 |
Free Cash Flow Growth | -26.86% | 110.34% | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Gross Margin | 64.66% | 64.66% | 60.59% | 56.33% | 45.48% | 45.54% |
Operating Margin | -6.93% | -6.93% | -5.40% | -20.04% | -99.92% | -77.97% |
Pretax Margin | 9.32% | 9.32% | -20.41% | -48.94% | -146.91% | -92.64% |
Profit Margin | 6.38% | 6.38% | -22.99% | -44.86% | 63.87% | -179.00% |
FCF Margin | 2.85% | 2.85% | 1.27% | -5.99% | -27.81% | -10.96% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 2, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
PE Ratio | 11.92 | 9.26 | - | - | 3.13 | - |
Forward PE | - | 150.33 | 150.33 | 150.33 | 150.33 | 150.33 |
P/FCF Ratio | 24.02 | 20.75 | 78.23 | - | - | - |
PS Ratio | 0.68 | 0.59 | 1.00 | 0.99 | 2.00 | 2.81 |